Blank, M., 		Mandel, M., 		Dror, N., 		Solomon, A., 		Barlyia, T., & 		Lavie, D.
2017 Mar 15.  Hypericin targets multiple signaling mediators in cancer cells generating unique, diverse anti-tumoral, anti-metastatic, and anti-angiogenic activities with evidence for clinical applicability. Medical Research Archives. [Online] 5:3